Luxshare Precision Industry Co., Ltd.
立讯精密
Luxshare Precision Industry Co., Ltd. is a Chinese precision manufacturing company frequently cited as a benchmark for industrial efficiency and vertical integration. In FreeS Fund's 2025 year-end analysis, Li Feng positioned it alongside firms like Lens Technology, Sunny Optical, and Goertek as exemplars of how China's consumer-electronics supply chain evolved from equipment manufacturing into precision manufacturing during 2010–2012, a stage he likened to where China's biotech sector stands today . The company has also been referenced as a model for "more efficient service outsourcing" in pharmaceutical infrastructure .
Luxshare appears across elsewhere's corpus primarily as a supply-chain partner and customer rather than as a profiled subject itself. It serves as a client for UHill Technology's intelligent decision-optimization systems , Diga Robotics' RDK S100-based robot controller initiative , and Wance's industrial sensors and safety solutions . In tariff-war coverage from April 2025, 暗涌Waves noted that Luxshare was among the Chinese exporters that had shifted U.S.-bound production to America or Mexico to sidestep duties . elsewhere's corpus does not contain a dedicated company profile or founding history for Luxshare Precision Industry.
AI-generated — may contain errors, please verify.
Coverage
"Wance" Closes Over 100 Million RMB Series A+ Funding, Secures Consecutive Orders From Multiple Industry Benchmark Companies | Linear Portfolio
Annual revenue growth exceeded 200%.
线性资本·FreeS Fund's Li Feng 2025 Year-End Share: The Logic and Outlook of AI Investment
Why Is This AI Boom Unprecedented? What Happens Next for AI Investment?
峰瑞资本·The First Newsletter of Autumn | Linear Quarterly
Cycles turn, and Wanwu Capital begins to harvest.
线性资本·Conversations with 30 Tariff War Veterans: Hope for the Best, Prepare for the Worst
A Self-Rescue Guide.
暗涌Waves·5Y News | 5Y Capital Portfolio Company UHill Technology Closes 100 Million RMB Series C Funding Round
Leading the upgrade of supply chain planning in the era of intelligent manufacturing.
五源资本·FreeS Report 23: Crossing the "Valley of Death": Systemic New Opportunities in Small-Molecule Drug R&D
Across every stage of preclinical drug R&D, new infrastructure, methods, and tools are emerging in China — making rapid, low-cost experimentation possible.
峰瑞资本·One Chart to Understand Globalization vs. Deglobalization | Li Feng Column
A Piece of History, Two Industries, Eight Companies: Understanding the Global Supply Chain
峰瑞资本·






